Immunocellular Therapeutics

Immunocellular Therapeutics Phase 3 ICT 107 Vaccine Clinical Trial for Glioblastoma Patients

ICT 107 is a vaccine for glioblastoma cancer stem cells.  This vaccine was developed by a company called ImmunoCellular Therapeutics, (https://www.imuc.com ) primarily by researchers at Cedars Sinai in Los Angeles.  https://virtualtrials.com/newsarticle.cfm?item=6107  This protocol has completed phase II testing and now it is open to a phase 3 randomized double blind control study for newly diagnosed glioblastoma.  […]

Update on Phase II Trial by Immunocellular Therapeutics ICT 107 for Newly Diagnosed Glioblastoma

Charles S. Cobbs, MD The Gregory Foltz, MD Endowed Director Ben & Catherine Ivy Center for Advanced Brain Tumor Treatment Swedish Neuroscience Specialists   A recent presentation at the American Society for Clinical Oncology  (ASCO) meeting in Chicago this month shows some suggestion of efficacy of the ImmunoCellular Therapeutics immunotherapy vaccine ICT-107.   http://www.marketwatch.com/story/immunocellular-therapeutics-presents-updated-ict-107-phase-ii-data-in-patients-with-newly-diagnosed-glioblastoma-at-the-2014-asco-annual-meeting-2014-06-01  The vaccine […]